Syngene’s Bengaluru unit passes US FDA test but with VAI classification

June 13, 2025
Uncategorized

The facility can continue selling approved drugs and will also receive approvals for new filings. Shares of Syngene International Ltd ended at ₹652.45, down by ₹10.45, or 1.58%, on the BSE.

Syngene’s Bengaluru unit passes US FDA test but with VAI classification

Leave a ReplyCancel Reply

Allcargo Terminals reports marginal decline in June Container Freight Station volumes

Ajmera Realty Q1 sales slump 65% YoY, but collections rise 42%

Wockhardt to exit US generics business, files for voluntary liquidation of two subsidiaries

Gland Pharma gets quality certification from Danish regulator for Pashamylaram facility

TCS salary hike: ‘No decision taken yet,’ says HR head